articleEMA’s transformative treatments of 202024 February 2021 | By Hannah Balfour (European Pharmaceutical Review)In this article, we summarise the trial findings for the European Medicines Agency’s 13 most transformative therapies of 2020.
newsNICE recommends Rozlytrek (entrectinib) as treatment for NSCLC16 June 2020 | By Victoria Rees (European Pharmaceutical Review)After three clinical trials showing its efficacy, NICE has recommended Rozlytrek (entrectinib) as treatment for non-small cell lung cancer (NSCLC).
newsFDA grants Rozlytrek cancer treatment approval16 August 2019 | By Victoria Rees (European Pharmaceutical Review)The cancer therapeutic, Rozlytrek, has gained FDA approval as well as Priority Review, Breakthrough Therapy and Orphan Drug Designations.